Avid Bioservices Inc (CDMO)

[entdoc]

Hypi, you're right about BigPharm money being able to shut out newcomers. And the biggest players are undeniably able to more easily market marginally effective goods. However, I think that in the past few years PPHM has demonstrated its staying power, and at this point an explosion in share price is entirely possible .... dependent on the trial numbers generated. The numbers cannot be marginal, and must be convincing. If "naked" Bavi does not come to market as an immunological stimulant, it could be a while before fully human Bavi armed with a cancercidal agent can come to market. At worst PPHM will become a boutique monoclonal antibody production company. "MABs account for 40 percent of the entire biotech drug market – and the market share keeps increasing. Sales are projected to reach more than $160 billion in the US alone over the next few years. Of the ten best-selling drugs in 2012, six of them were monoclonal antibody drugs, each with annual sales value exceeding US$5 billion.
Some biotech companies have attracted billion dollar price tags. In 2008, Eli Lilly & Co. acquired ImClone Systems, Inc. for $6.5 billion. ImClone’s only product – Erbitux®– had generated annual sales of approximately $1.3 billion in 2007. Therefore, ImClone was valued at a 5x multiple to prior year sales. In 2009, Bristol-Myers Squibb acquired Medarex, Inc. for $2.4 billion, offering $16 per share – a 90 percent premium to Medarex’s closing share price the same day." And Hypi, please believe me, Erbitux is not a patch on Bavituximab. Not even close! PPHM has other very good potential tickets in their portfolio that have not even been more than mentioned in the past few years. PPHM and Bavi are the real deal Hypi.


Monoclonal Antibodies Continue to Drive Biotech Investment
Debbie Stephenson October 23, 2013 www.firmex.com › Blog › Dealmaker News › Industry Trends